Avantis International Small Cap Value ETF vs Neurocrine Biosciences Inc — how do they compare? Avantis International Small Cap Value ETF trades at $110.23, while Neurocrine Biosciences Inc trades at $157.29 (market cap $16.46B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| AVDV | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $185.50 |
52-Week Low | $83.89 | $123.10 |
Market Cap | — | $16.46B |
Enterprise Value | — | $16.48B |
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $110.51, up 0.96% today, with a bullish technical outlook from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies gaining attention. The stock shows support near $108-$109 and resistance at $110.
The outlook remains positive due to momentum in international small-cap value, though overbought signals and reliance on commodity sectors pose risks. Investors should weigh the ETF's diversification benefits against potential volatility from global economic shifts.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →